SCHEMBL20135150

SCHEMBL20135150

CCOC(=O)CC(C#N)(C(=O)OC(C)(C)C)c1ccc(C(=O)OCC)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
CA14 Q9ULX7 2/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
TSHR P16473 1/20 0.34
TLR4 O00206 1/20 0.34
TLR2 O60603 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135688 0.90 MAPT (0.38) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20134843 0.81 MAPT (0.40) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20791725 0.76 CA12 (0.36) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20135375 0.74 MAPT (0.41) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL12868073 0.73 KMT2A (0.54) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20134842 0.70 SMN1; SMN2 (0.49) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL838555 0.70 CA12 (0.49) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20791683 0.69 MAPT (0.39) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20135239 0.68 MAPT (0.39) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL20135236 0.68 MAPT (0.39) MAPTKDM4ENPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885KDM4E 725/4885NPC1 4881/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885KDM4E 723/4885NPC1 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.